Search

everythinglearnresearchcommunity

for

Search:↓

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

EGFR-TKIs can cause significant skin, nail, and organ side effects.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Ruxolitinib helped a man regrow his beard after years of hair loss.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Ritlecitinib can help about 14,000 people with severe hair loss.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

BBR-SA nanomedicine is a safe and effective treatment for breast cancer.

JAK inhibitors effectively treat skin conditions and topical forms are safer.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Ruxolitinib can help regrow hair in severe alopecia areata.